Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

New Horizon Stages $263 Million HK IPO for Cancer Screening Tests

publication date: Feb 22, 2021

New Horizon Health staged a $263 million IPO last week on the Hong Kong Exchange to support its early cancer screening tests. The stock tripled in trading, giving the company a market cap of $4.3 billion. New Horizon markets two stool based tests in China: ColoClear, a multi-target, FIT-DNA test aimed at people at risk for colorectal cancer, and Pupu Tube, a self-administered FIT test intended to screen a larger population. The company also has two late-stage product candidates for gastric and cervical cancer screening. More details....

Stock Symbol: (HK: 6606)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.